Minoxidil
Minoxidil, Rogaine, Theroxidil (minoxidil) is a small molecule pharmaceutical. Minoxidil was first approved as Loniten on 1982-01-01. It is used to treat alopecia and malignant hypertension in the USA.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Therapeutic Areas
Trade Name
FDA
EMA
Minoxidil, Rogaine (discontinued: Loniten, Minoxidil)
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Minoxidil
Tradename | Company | Number | Date | Products |
|---|---|---|---|---|
| ROGAINE (FOR MEN) | Johnson & Johnson | N-019501 OTC | 1996-02-09 | 1 products, RLD, RS |
| ROGAINE (FOR WOMEN) | Johnson & Johnson | N-019501 OTC | 1996-02-09 | 1 products, RLD, RS |
| ROGAINE EXTRA STRENGTH (FOR MEN) | Johnson & Johnson | N-020834 OTC | 1997-11-14 | 1 products, RLD, RS |
| MEN'S ROGAINE | Johnson & Johnson | N-021812 OTC | 2006-01-20 | 1 products, RLD, RS |
| WOMEN'S ROGAINE | Johnson & Johnson | N-021812 OTC | 2014-02-28 | 1 products, RLD, RS |
Show 1 discontinued
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| 10% de minoxidil | C200263 | 2025-01-11 |
| 10%de minoxidil | C200263 | 2024-11-04 |
| 2% minoxidil hair growth oil | ANDA | 2023-11-02 |
| 2% minoxidil hair growth serum | C200263 | 2024-08-30 |
| 2% minoxidil hair regrowth foam | C200263 | 2024-12-11 |
| 2% minoxidil hair regrowth serum | ANDA | 2023-10-11 |
| 3rx minoxidil hair regrowth treatment for men | unapproved drug other | 2024-06-18 |
| 5 minoxidil hair foam with biotin | C200263 | 2024-10-14 |
| 5% minoxidil | ANDA | 2023-12-22 |
| 5% minoxidil foam | C200263 | 2024-09-12 |
Show 290 more
Indications
FDA
EMA
Indication | Ontology | MeSH | ICD-10 |
|---|---|---|---|
| alopecia | — | D000505 | L64 |
| malignant hypertension | EFO_1001031 | D006974 | — |
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
ATC Codes
C: Cardiovascular system drugs
— C02: Antihypertensives
— C02D: Arteriolar smooth muscle, agents acting on
— C02DC: Pyrimidine derivatives acting on arteriolar smooth muscle
— C02DC01: Minoxidil
D: Dermatologicals
— D11: Other dermatological preparations in atc
— D11A: Other dermatological preparations in atc
— D11AX: Other dermatological preparations in atc
— D11AX01: Minoxidil
HCPCS
Code | Description |
|---|---|
| S0139 | Minoxidil, 10 mg |
Clinical
Clinical Trials
93 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Alopecia | D000505 | — | L64 | 14 | 23 | 18 | 7 | 19 | 72 |
| Alopecia areata | D000506 | EFO_0004192 | L63 | 10 | 19 | 15 | 4 | 15 | 57 |
| Hypotrichosis | D007039 | — | — | 1 | — | — | 2 | — | 3 |
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Kidney diseases | D007674 | EFO_0003086 | N08 | — | — | 1 | — | — | 1 |
| Polycystic kidney diseases | D007690 | — | Q61.3 | — | — | 1 | — | — | 1 |
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Drug-related side effects and adverse reactions | D064420 | — | T88.7 | 1 | 1 | — | — | — | 1 |
| Self-assessment | D012647 | — | — | 1 | 1 | — | — | — | 1 |
| Syndrome | D013577 | — | — | — | 1 | — | — | — | 1 |
| Williams syndrome | D018980 | Orphanet_904 | Q93.82 | — | 1 | — | — | — | 1 |
| Ovarian neoplasms | D010051 | EFO_0003893 | C56 | — | 1 | — | — | — | 1 |
| Ovarian epithelial carcinoma | D000077216 | — | — | — | 1 | — | — | — | 1 |
| Acne vulgaris | D000152 | EFO_0003894 | L70 | 1 | 1 | — | — | — | 1 |
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Breast neoplasms | D001943 | EFO_0003869 | C50 | 2 | — | — | — | — | 2 |
| Healthy volunteers/patients | — | — | — | 1 | — | — | — | — | 1 |
| Pharmacokinetics | D010599 | — | — | 1 | — | — | — | — | 1 |
| Mammaplasty | D016462 | — | — | 1 | — | — | — | — | 1 |
| Genetic predisposition to disease | D020022 | — | — | 1 | — | — | — | — | 1 |
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Hypertension | D006973 | EFO_0000537 | I10 | — | — | — | — | 3 | 3 |
| Covid-19 | D000086382 | — | U07.1 | — | — | — | — | 1 | 1 |
| Fissure in ano | D005401 | — | K60.2 | — | — | — | — | 1 | 1 |
| Wounds and injuries | D014947 | — | T14.8 | — | — | — | — | 1 | 1 |
| Wound healing | D014945 | GO_0042060 | — | — | — | — | — | 1 | 1 |
| Premature birth | D047928 | EFO_0003917 | O60 | — | — | — | — | 1 | 1 |
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Minoxidil |
| INN | minoxidil |
| Description | Minoxidil is a pyrimidine N-oxide that is pyrimidine-2,4-diamine 3-oxide substituted by a piperidin-1-yl group at position 6. It has a role as a vasodilator agent and an antihypertensive agent. It is a pyrimidine N-oxide, a member of piperidines and an aminopyrimidine. |
| Classification | Small molecule |
| Drug class | vasodilators (undefined group) |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | Nc1cc(N2CCCCC2)nc(N)[n+]1[O-] |
Identifiers
| PDB | — |
| CAS-ID | 38304-91-5 |
| RxCUI | — |
| ChEMBL ID | CHEMBL802 |
| ChEBI ID | 6942 |
| PubChem CID | 4201 |
| DrugBank | DB00350 |
| UNII ID | 5965120SH1 (ChemIDplus, GSRS) |
Target
No data
Variants
No data
Financial
Revenue by drug
$
€
£
₣
No data
Estimated US medical usage
Minoxidil
Total medical expenditures per year (USD, in millions)
Mock data
Subscribe for the real data
Subscribe for the real data
Number of persons purchased
Mock data
Subscribe for the real data
Subscribe for the real data
Number of purchases
Mock data
Subscribe for the real data
Subscribe for the real data
Refill frequency
Mock data
Subscribe for the real data
Subscribe for the real data
Price per prescription (USD)
Mock data
Subscribe for the real data
Subscribe for the real data
Tabular view
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 5,332 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
61,687 adverse events reported
View more details
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use